{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:41:32Z","timestamp":1770748892109,"version":"3.50.0"},"reference-count":62,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Antibiotic treatment (ABT) has been associated with worse outcomes of cancer immunotherapy. However, this association might be confounded by other poor prognostic factors. We aimed to evaluate the use of ABT and outcomes of immune checkpoint inhibitors (ICI) in metastatic kidney cancer (mRCC).Patient\/material and methods: We identified retrospectively 192 patients treated with ICI for mRCC between 2015 and 2021 at three academic hospitals in Finland. Information on patient characteristics, ABT, and immunotherapy was collected from electronic medical records. Cox regression and Kaplan-Meier methods were used for survival analyses. Results: A total of 61 (32%) patients had received early ABT (3 months before and 1 month after the first dose of ICI), of whom 31 (51%) had ABT &gt; 7 days. Patients with early ABT had shorter median overall survival (mOS) than patients without early ABT (20.4 vs 27.9 months, p = 0.046). Patients with ABT &gt; 7 days had shorter mOS than patients with ABT 0\u20137 days (17.2 vs 27.5 months, p = 0.015). After adjustment for International Metastatic Renal Cell Carcinoma Database Consortium risk groups, histological renal cell carcinoma subtype, baseline levels of C-reactive protein, and tumor burden, the risk of death was higher in patients with ABT &gt; 7 days (hazard ratio 1.83 (95% confidence interval 1.06\u20133.17). No significant differences in progression-free survival times (PFS) were observed.Interpretation: Early ABT and prolonged ABT duration were associated with shorter OS, but not with PFS, in patients treated with ICI for mRCC. Prolonged ABT indicated poor prognosis regardless of other risk factors.<\/jats:p>","DOI":"10.2340\/1651-226x.2026.44974","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:34:01Z","timestamp":1770712441000},"page":"83-89","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic treatment indicates shorter survival in patients with immunotherapy for metastatic kidney cancer"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8871-6323","authenticated-orcid":false,"given":"Elisa","family":"Kankkunen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-5448","authenticated-orcid":false,"given":"Kaisa Sunela","family":"Sunela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-5934","authenticated-orcid":false,"given":"Timo Makkonen","family":"Makkonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-193X","authenticated-orcid":false,"given":"Katriina Jalkanen","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-9187","authenticated-orcid":false,"given":"Kalle","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"141051","doi-asserted-by":"crossref","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Gr\u00fcnwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692\u2013706. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537[2","DOI":"10.1016\/j.annonc.2024.05.537"},{"key":"141052","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","DOI":"10.1056\/NEJMoa1712126"},{"key":"141053","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1712126","DOI":"10.1056\/NEJMoa1712126"},{"key":"141054","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31:1030\u20139.","DOI":"10.1016\/j.annonc.2020.04.010"},{"key":"141055","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2020.04.010","DOI":"10.1016\/j.annonc.2020.04.010"},{"key":"141056","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829\u201341.","DOI":"10.1056\/NEJMoa2026982"},{"key":"141057","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2026982","DOI":"10.1056\/NEJMoa2026982"},{"key":"141058","doi-asserted-by":"crossref","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289\u2013300.","DOI":"10.1056\/NEJMoa2035716"},{"key":"141059","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2035716","DOI":"10.1056\/NEJMoa2035716"},{"key":"141060","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ,"},{"key":"141061","doi-asserted-by":"crossref","unstructured":"Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","DOI":"10.1056\/NEJMoa1510665"},{"key":"141062","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1510665","DOI":"10.1056\/NEJMoa1510665"},{"key":"141063","unstructured":"Jespersen MS, Palshof JAE, Fristrup N, Jensen NV, Henriksen JR,"},{"key":"141064","doi-asserted-by":"crossref","unstructured":"Iversen ABB, et al. Nationwide real-world outcomes of trial eligible and trial ineligible patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Clin Genitourin Cancer. 2025;23:102450.","DOI":"10.1016\/j.clgc.2025.102450"},{"key":"141065","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102450","DOI":"10.1016\/j.clgc.2025.102450"},{"key":"141066","doi-asserted-by":"crossref","unstructured":"Kheir A, Johannsdottir B, Gr\u00f6nn-Weiss A, Liu LL, Ull\u00e9n A, Laurell A, et al. Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab. Acta Oncol. 2025;64:1355\u201364.","DOI":"10.2340\/1651-226X.2025.44533"},{"key":"141067","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/1651-226x.2025.44533","DOI":"10.2340\/1651-226X.2025.44533"},{"key":"141068","doi-asserted-by":"crossref","unstructured":"McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the \u00admicrobiome to improve therapeutic response in cancer. Lancet Oncol. 2019;20:e77\u201391.","DOI":"10.1016\/S1470-2045(18)30952-5"},{"key":"141069","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(18)30952-5","DOI":"10.1016\/S1470-2045(18)30952-5"},{"key":"141070","doi-asserted-by":"crossref","unstructured":"Routy B, Jackson T, M\u00e4hlmann L, Baumgartner CK, Blaser M, Byrd A, et al. Melanoma and microbiota: current understanding and future directions. Cancer Cell. 2024;42:16\u201334.","DOI":"10.1016\/j.ccell.2023.12.003"},{"key":"141071","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ccell.2023.12.003","DOI":"10.1016\/j.ccell.2023.12.003"},{"key":"141072","doi-asserted-by":"crossref","unstructured":"Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78:195\u2013206.","DOI":"10.1016\/j.eururo.2020.04.044"},{"key":"141073","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2020.04.044","DOI":"10.1016\/j.eururo.2020.04.044"},{"key":"141074","doi-asserted-by":"crossref","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079\u201384.","DOI":"10.1126\/science.aad1329"},{"key":"141075","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/science.aad1329","DOI":"10.1126\/science.aad1329"},{"key":"141076","doi-asserted-by":"crossref","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104\u20138.","DOI":"10.1126\/science.aao3290"},{"key":"141077","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/science.aao3290","DOI":"10.1126\/science.aao3290"},{"key":"141078","doi-asserted-by":"crossref","unstructured":"Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, et al. Antibiotics are associated with decreased progression-free \u00adsurvival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8:e1568812.","DOI":"10.1080\/2162402X.2019.1568812"},{"key":"141079","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/2162402x.2019.1568812","DOI":"10.1080\/2162402X.2019.1568812"},{"key":"141080","doi-asserted-by":"crossref","unstructured":"Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur Urol. 2020;78:498\u2013502.","DOI":"10.1016\/j.eururo.2020.07.011"},{"key":"141081","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2020.07.011","DOI":"10.1016\/j.eururo.2020.07.011"},{"key":"141082","doi-asserted-by":"crossref","unstructured":"Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5:1774\u20138.","DOI":"10.1001\/jamaoncol.2019.2785"},{"key":"141083","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.2785","DOI":"10.1001\/jamaoncol.2019.2785"},{"key":"141084","unstructured":"Ouaknine Krief J, Helly de Tauriers P, Dumenil C, Neveux N, Dumoulin J,"},{"key":"141085","doi-asserted-by":"crossref","unstructured":"Giraud V, et al. Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. J Immunother Cancer. 2019;7:176.","DOI":"10.1186\/s40425-019-0658-1"},{"key":"141086","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s40425-019-0658-1","DOI":"10.1186\/s40425-019-0658-1"},{"key":"141087","doi-asserted-by":"crossref","unstructured":"Lalani A-KA, Xie W, Braun DA, Kaymakcalan M, Boss\u00e9 D, Steinharter JA, et al. Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. Eur Urol Oncol. 2020;3:372\u201381.","DOI":"10.1016\/j.euo.2019.09.001"},{"key":"141088","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2019.09.001","DOI":"10.1016\/j.euo.2019.09.001"},{"key":"141089","unstructured":"Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M,"},{"key":"141090","doi-asserted-by":"crossref","unstructured":"Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437\u201344.","DOI":"10.1093\/annonc\/mdy103"},{"key":"141091","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdy103","DOI":"10.1093\/annonc\/mdy103"},{"key":"141092","doi-asserted-by":"crossref","unstructured":"Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, et al. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. Oncologist. 2020;25:55\u201363.","DOI":"10.1634\/theoncologist.2019-0160"},{"key":"141093","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0160","DOI":"10.1634\/theoncologist.2019-0160"},{"key":"141094","doi-asserted-by":"crossref","unstructured":"Jung H-J, Park J-H, Oh J, Lee S-M, Jang I-Y, Hong J-Y, et al. Adverse effect of the duration of antibiotic use prior to immune checkpoint inhibitors on the overall survival of patients with recurrent gynecologic malignancies. Cancers. 2023;15:5745.","DOI":"10.3390\/cancers15245745"},{"key":"141095","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers15245745","DOI":"10.3390\/cancers15245745"},{"key":"141096","doi-asserted-by":"crossref","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103.","DOI":"10.1126\/science.aan4236"},{"key":"141097","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/science.aan4236","DOI":"10.1126\/science.aan4236"},{"key":"141098","doi-asserted-by":"crossref","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137.","DOI":"10.1126\/science.aan3706"},{"key":"141099","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/science.aan3706","DOI":"10.1126\/science.aan3706"},{"key":"141100","doi-asserted-by":"crossref","unstructured":"Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022;15:47.","DOI":"10.1186\/s13045-022-01273-9"},{"key":"141101","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13045-022-01273-9","DOI":"10.1186\/s13045-022-01273-9"},{"key":"141102","doi-asserted-by":"crossref","unstructured":"Wilson BE, Routy B, Nagrial A, Chin VT. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol Immunother. 2020;69:343\u201354.","DOI":"10.1007\/s00262-019-02453-2"},{"key":"141103","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00262-019-02453-2","DOI":"10.1007\/s00262-019-02453-2"},{"key":"141104","doi-asserted-by":"crossref","unstructured":"Crespin A, Le Bescop C, de Gunzburg J, Vitry F, Zalcman G, Cervesi J, et al. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front Oncol. 2023;13:1075593.","DOI":"10.3389\/fonc.2023.1075593"},{"key":"141105","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2023.1075593","DOI":"10.3389\/fonc.2023.1075593"},{"key":"141106","doi-asserted-by":"crossref","unstructured":"Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374:1632\u201340.","DOI":"10.1126\/science.aaz7015"},{"key":"141107","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/science.aaz7015","DOI":"10.1126\/science.aaz7015"},{"key":"141108","doi-asserted-by":"crossref","unstructured":"Byron Y, Yegorova-Lee S, Tio M. Do corticosteroids affect immunotherapy efficacy in malignancy? \u2013 a systematic review. Cancer Med. 2024;13:e70254.","DOI":"10.1002\/cam4.70254"},{"key":"141109","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.70254","DOI":"10.1002\/cam4.70254"},{"key":"141110","unstructured":"Lefort F, Dalban C, Gross-Goupil M, Laguerre B, Chabaud S, Escudier B,"},{"key":"141111","doi-asserted-by":"crossref","unstructured":"et al. Association of corticosteroids with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. JAMA Oncol. 2023;9:1295\u20138.","DOI":"10.1001\/jamaoncol.2023.2296"},{"key":"141112","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.2296","DOI":"10.1001\/jamaoncol.2023.2296"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44974\/52824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44974\/52824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:34:21Z","timestamp":1770712461000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/44974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":62,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.44974","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}